Table 1. Inhibition of luciferase expression in LFCLI1 cells by F1- and F2-encapsulated C-5 propyne phosphorothioate oligonucleotide (500 nM) compared to the free oligonucleotide.
| Spherulite™ formulations | F1 | F2 | |
|---|---|---|---|
| t = 24 h | t = 24 h | t = 48 h | |
| Untreated Cells | 100.0 ± 4.8 | 100.0 ± 5.1 | 100.0 ± 3.2 |
| + Non encapsulated Lucif-2 | 83.1 ± 2.1 | 82.3 ± 1.0 | 92.0 ± 1.1 |
| + Non encapsulated Lucif-2MM | 92.0 ± 2.0 | 91.0 ± 2.2 | 99.9 ± 5.6 |
| + Empty vesicles | 62.3 ± 4.2 | 95.1 ± 0.9 | 96.5 ± 2.1 |
| + Encapsulated Lucif-2 | 38.6 ± 3.0 | 71.4 ± 0.5 | 52.1 ± 1.0 |
| + Encapsulated Lucif-2MM | 69.8 ± 4.5 | 88.7 ± 2.2 | 74.1 ± 3.2 |
The lipid concentration was 0.25 mg/ml for F1 and 0.3 mg/ml for F2 formulations. Normalised relative light units corresponding to luciferase expression of treated cells are given. Luciferase activity of untreated cells was chosen as 100% of luciferase expression. Results are given as means ± SD.